Naoto T Ueno

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2474462/publications.pdf

Version: 2024-02-01

341 papers	17,936 citations	17405 63 h-index	18606 119 g-index
355 all docs	355 docs citations	355 times ranked	27293 citing authors

#	Article	IF	Citations
1	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature, 2016, 534, 47-54.	13.7	1,760
2	Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes. Clinical Cancer Research, 2013, 19, 5533-5540.	3.2	597
3	Melphalan and purine analogâ€“containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood, 2001, 97, 631-637.	0.6	551
4	Bone Imaging in Metastatic Breast Cancer. Journal of Clinical Oncology, 2004, 22, 2942-2953.	0.8	546
5	A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer. JAMA - Journal of the American Medical Association, 2011, 305, 1873.	3.8	531
6	Role of epidermal growth factor receptor in breast cancer. Breast Cancer Research and Treatment, 2012, 136, 331-345.	1.1	529
7	Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. Journal of Clinical Oncology, 2015, 33, 2753-2762.	0.8	372
8	Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors. Journal of Clinical Oncology, 2012, 30, 593-599.	0.8	361
9	Inflammatory Breast Cancer: The Disease, the Biology, the Treatment. Ca-A Cancer Journal for Clinicians, 2010, 60, 351-375.	157.7	298
10	Dependence of Paclitaxel Sensitivity on a Functional Spindle Assembly Checkpoint. Cancer Research, 2004, 64, 2502-2508.	0.4	248
11	Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemotherapy and Pharmacology, 1997, 40, 321-329.	1.1	242
12	Inflammatory breast cancer biology: the tumour microenvironment is key. Nature Reviews Cancer, 2018, 18, 485-499.	12.8	235
13	Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry. Journal of Clinical Oncology, 2012, 30, 729-734.	0.8	231
14	Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. Nature, 2017, 543, 714-718.	13.7	229
15	Cationic Liposome-MediatedE1AGene Transfer to Human Breast and Ovarian Cancer Cells and Its Biologic Effects: A Phase I Clinical Trial. Journal of Clinical Oncology, 2001, 19, 3422-3433.	0.8	207
16	Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST. Journal of Cancer, 2010, 1, 80-92.	1.2	205
17	Inflammatory breast cancer (IBC) and patterns of recurrence. Cancer, 2007, 110, 1436-1444.	2.0	194
18	Epithelialâ€“Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer. Molecular Cancer Therapeutics, 2012, 11, 2526-2534.	1.9	194

#	Article	IF	Citations
19	Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Research, 2011, 13, R67.	2.2	188
20	Microfluidics separation reveals the stem-cellâ€“like deformability of tumor-initiating cells. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 18707-18712.	3.3	186
21	Prognostic Value of Nodal Ratios in Node-Positive Breast Cancer. Journal of Clinical Oncology, 2006, 24, 2910-2916.	0.8	178
22	Disulfiram (DSF) acts as a copper ionophore to induce copperâ€dependent oxidative stress and mediate antiâ€tumor efficacy in inflammatory breast cancer. Molecular Oncology, 2015, 9, 1155-1168.	2.1	168
23	Androgen Receptor Function and Androgen Receptorâ€“Targeted Therapies in Breast Cancer. JAMA Oncology, 2017, 3, 1266.	3.4	166
24	Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncology, The, 2009, 10, 606-614.	5.1	154
25	Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood, 2003, 102, 3829-3836.	0.6	143
26	Circulating Tumor Cells in Metastatic Breast Cancer: Biologic Staging Beyond Tumor Burden. Clinical Breast Cancer, 2007, 7, 34-42.	1.1	141
27	Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica, 2008, 93, 257-264.	1.7	141
28	Circulating Tumor Cells and [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Outcome Prediction in Metastatic Breast Cancer. Journal of Clinical Oncology, 2009, 27, 3303-3311.	0.8	139
29	Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, HerceptinÂ®) conjugated polyethylenimine. Journal of Controlled Release, 2004, 97, 357-369.	4.8	138
30	Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets. Clinical Cancer Research, 2013, 19, 4685-4696.	3.2	130
31	Targeting EGFR in Triple Negative Breast Cancer. Journal of Cancer, 2011, 2, 324-328.	1.2	128
32	Inflammatory Breast Cancer: What We Know and What We Need to Learn. Oncologist, 2012, 17, 891-899.	1.9	127
33	Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early. Cancer, 2011, 117, 1819-1826.	2.0	121
34	Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells. PLoS ONE, 2015, 10, e0132710.	1.1	121
35	Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Annals of Oncology, 2017, 28, 2420-2428.	0.6	114
36	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer. Clinical Cancer Research, 2009, 15, 6639-6648.	3.2	113

#	Article	IF	Citations
37	Underuse of Trimodality Treatment Affects Survival for Patients With Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends From the National Cancer Database. Journal of Clinical Oncology, 2014, 32, 2018-2024.	0.8	113
38	Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nature Communications, 2021, 12, 3528.	5.8	108
39	Acquired Resistance to Erlotinib in A-431 Epidermoid Cancer Cells Requires Down-regulation of MMAC1/PTEN and Up-regulation of Phosphorylated Akt. Cancer Research, 2007, 67, 5779-5788.	0.4	107
40	Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. International Journal of Cancer, 2011, 129, 417-423.	2.3	101
41	Histone Deacetylase Inhibitors Stimulate Dedifferentiation of Human Breast Cancer Cells Through WNT/Î²â€Catenin Signaling. Stem Cells, 2012, 30, 2366-2377.	1.4	100
42	Future directions of bone-targeted therapy for metastatic breast cancer. Nature Reviews Clinical Oncology, 2010, 7, 641-651.	12.5	97
43	Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Research, 2014, 16, 440.	2.2	94
44	Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. Oncotarget, 2015, 6, 12890-12908.	0.8	92
45	High Serum miR-19a Levels Are Associated with Inflammatory Breast Cancer and Are Predictive of Favorable Clinical Outcome in Patients with Metastatic HER2+ Inflammatory Breast Cancer. PLoS ONE, 2014, 9, e83113.	1.1	91
46	Bone Metastasis of Breast Cancer. Advances in Experimental Medicine and Biology, 2019, 1152, 105-129.	0.8	90
47	High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials. Journal of Clinical Oncology, 2011, 29, 3214-3223.	0.8	89
48	Relationship Between Lymphocytopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast Cancer. Clinical Breast Cancer, 2012, 12, 264-269.	1.1	87
49	Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene, 1997, 15, 953-960.	2.6	86
50	Triple-Negative Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer. Oncologist, 2011, 16, 1675-1683.	1.9	86
51	International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. Journal of Cancer, 2018, 9, 1437-1447.	1.2	84
52	Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. International Journal of Clinical Oncology, 2012, 17, 96-104.	1.0	80
53	Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models. Oncotarget, 2016, 7, 82482-82492.	0.8	78
54	Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer, 2001, 92, 1775-1782.	2.0	76

#	Article	IF	Citations
55	Inflammatory breast cancer: a proposed conceptual shift in the UICCâ€“AJCC TNM staging system. Lancet Oncology, The, 2017, 18, e228-e232.	5.1	74
56	FDG-PET/CT Compared with Conventional Imaging in the Detection of Distant Metastases of Primary Breast Cancer. Oncologist, 2011, 16, 1111-1119.	1.9	73
57	Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Molecular Cancer Therapeutics, 2008, 7, 1846-1850.	1.9	70
58	TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase. Cancer Research, 2013, 73, 6516-6525.	0.4	70
59	miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer. Journal of the National Cancer Institute, 2016, 108, djw026.	3.0	70
60	Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. Cancer Immunology Research, 2019, 7, 1025-1035.	1.6	70
61	Simvastatin Radiosensitizes Differentiated and Stem-Like Breast Cancer Cell Lines and Is Associated With Improved Local Control in Inflammatory Breast Cancer Patients Treated With Postmastectomy Radiation. Stem Cells Translational Medicine, 2014, 3, 849-856.	1.6	69
62	Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Research and Treatment, 2011, 125, 785-795.	1.1	68
63	Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Research and Treatment, 2015, 152, 407-416.	1.1	68
64	Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clinical Breast Cancer, 2007, 7, 471-9.	1.1	67
65	High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Transplantation in Metastatic Breast Cancer: Overview of Six Randomized Trials. Journal of Clinical Oncology, 2011, 29, 3224-3231.	0.8	66
66	Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Molecular Cancer Therapeutics, 2007, 6, 2168-2177.	1.9	65
67	Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells. Breast Cancer Research, 2009, 11, R12.	2.2	65
68	Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. Journal of Cancer, 2012, 3, 369-380.	1.2	65
69	Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer. JAMA Oncology, 2015, 1, 1311.	3.4	65
70	Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. British Journal of Haematology, 2002, 119, 131-134.	1.2	64
71	Inflammatory Breast Cancer. Surgical Clinics of North America, 2018, 98, 787-800.	0.5	63
72	PEA-15 Induces Autophagy in Human Ovarian Cancer Cells and Is Associated with Prolonged Overall Survival. Cancer Research, 2008, 68, 9302-9310.	0.4	62

#	Article	IF	Citations
73	Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer, 2011, 117, 5476-5484.	2.0	61
74	MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model. Molecular Cancer Therapeutics, 2015, 14, 2773-2781.	1.9	61
75	¹⁸F-FDG PET/CT Findings and Circulating Tumor Cell Counts in the Monitoring of Systemic Therapies for Bone Metastases from Breast Cancer. Journal of Nuclear Medicine, 2010, 51, 1213-1218.	2.8	60
76	Improvement of survival and prospect of cure in patients with metastatic breast cancer. Breast Cancer, 2012, 19, 191-199.	1.3	60
77	Treatment Outcome and Prognostic Factors for Patients with Bone-Only Metastases of Breast Cancer: A Single-Institution Retrospective Analysis. Oncologist, 2011, 16, 155-164.	1.9	59
78	Novel therapeutic strategies in the treatment of triple-negative breast cancer. Therapeutic Advances in Medical Oncology, 2017, 9, 493-511.	1.4	58
79	Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. Cancer, 2014, 120, 1319-1328.	2.0	57
80	ST8SIA1 Regulates Tumor Growth and Metastasis in TNBC by Activating the FAKâ€“AKTâ€“mTOR Signaling Pathway. Molecular Cancer Therapeutics, 2018, 17, 2689-2701.	1.9	57
81	Genomic and expression analysis of microdissected inflammatory breast cancer. Breast Cancer Research and Treatment, 2013, 138, 761-772.	1.1	56
82	Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncology, 2018, 4, 1207.	3.4	56
83	Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism. Oncotarget, 2016, 7, 28329-28339.	0.8	54
84	The Role of Inflammation in Inflammatory Breast Cancer. Advances in Experimental Medicine and Biology, 2014, 816, 53-73.	0.8	53
85	Molecular targets for treatment of inflammatory breast cancer. Nature Reviews Clinical Oncology, 2009, 6, 387-394.	12.5	52
86	Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. Breast Cancer Research and Treatment, 2015, 154, 495-508.	1.1	52
87	Prognostic value of nodal ratios in node-positive breast cancer: a compiled update. Future Oncology, 2009, 5, 1585-1603.	1.1	51
88	JNK Signaling in Stem Cell Self-Renewal and Differentiation. International Journal of Molecular Sciences, 2020, 21, 2613.	1.8	50
89	Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model. Breast Cancer Research, 2015, 17, 42.	2.2	49
90	Body composition and breast cancer risk and treatment: mechanisms and impact. Breast Cancer Research and Treatment, 2021, 186, 273-283.	1.1	47

#	Article	IF	Citations
91	Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Research, 2013, 15, R112.	2.2	46
92	The Antihelmintic Drug Pyrvinium Pamoate Targets Aggressive Breast Cancer. PLoS ONE, 2013, 8, e71508.	1.1	46
93	cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. Journal of Cancer, 2014, 5, 745-753.	1.2	46
94	Maintenance of HCT116 colon cancer cell line conforms to a stochastic model but not a cancer stem cell model. Cancer Science, 2009, 100, 2275-2282.	1.7	45
95	Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. Breast Cancer Research, 2017, 19, 93.	2.2	45
96	Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Research, 2002, 62, 6712-6.	0.4	45
97	ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION AS ADOPTIVE IMMUNOTHERAPY. Hematology/Oncology Clinics of North America, 1999, 13, 1041-1057.	0.9	44
98	Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer. Expert Opinion on Investigational Drugs, 2017, 26, 463-479.	1.9	44
99	Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget, 2017, 8, 35656-35668.	0.8	44
100	Antagonism of Tumoral Prolactin Receptor Promotes Autophagy-Related Cell Death. Cell Reports, 2014, 7, 488-500.	2.9	43
101	Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. JCO Precision Oncology, 2018, 2018, 1-15.	1.5	43
102	Pretreatment Staging Positron Emission Tomography/Computed Tomography in Patients WithÂInflammatory Breast Cancer Influences RadiationÂTreatment Field Designs. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1381-1386.	0.4	42
103	Challenges and perspective of drug repurposing strategies in early phase clinical trials. Oncoscience, 2015, 2, 576-580.	0.9	42
104	EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. Oncotarget, 2017, 8, 67904-67917.	0.8	40
105	Differential Radiosensitizing Effect of Valproic Acid in Differentiation Versus Self-Renewal Promoting Culture Conditions. International Journal of Radiation Oncology Biology Physics, 2010, 76, 889-895.	0.4	39
106	The Medical Treatment of Inflammatory Breast Cancer. Seminars in Oncology, 2008, 35, 64-71.	0.8	38
107	PEA-15 Inhibits Tumorigenesis in an MDA-MB-468 Triple-Negative Breast Cancer Xenograft Model through Increased Cytoplasmic Localization of Activated Extracellular Signal-Regulated Kinase. Clinical Cancer Research, 2010, 16, 1802-1811.	3.2	38
108	A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. Breast Cancer Research and Treatment, 2014, 146, 259-272.	1.1	38

#	Article	IF	Citations
109	Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes and Control, 2016, 27, 359-366.	0.8	38
110	MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. Oncotarget, 2016, 7, 18531-18540.	0.8	38
111	Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer Metastasis. Cancer Research, 2020, 80, 1304-1315.	0.4	37
112	Receiving Information on Fertility- and Menopause-Related Treatment Effects among Women Who Undergo Hematopoietic Stem Cell Transplantation: Changes in Perceived Importance Over Time. Biology of Blood and Marrow Transplantation, 2009, 15, 1465-1474.	2.0	36
113	Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Research, 2015, 17, 2.	2.2	36
114	Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer. Clinical Cancer Research, 2017, 23, 4780-4792.	3.2	35
115	Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591986606.	1.4	35
116	Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. Oncotarget, 2017, 8, 14897-14911.	0.8	35
117	A novel hTERT promoterâ€“driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics, 2009, 8, 2375-2382.	1.9	34
118	Prognosis for patients with metastatic breast cancer who achieve a noâ€evidenceâ€ofâ€disease status after systemic or local therapy. Cancer, 2015, 121, 4324-4332.	2.0	34
119	Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation Sequencing. American Journal of Clinical Pathology, 2015, 144, 713-721.	0.4	34
120	Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype. PLoS ONE, 2018, 13, e0204513.	1.1	34
121	Functional consequence of theMET-T1010I polymorphism in breast cancer. Oncotarget, 2015, 6, 2604-2614.	0.8	34
122	A Prospective Study of Bone Tumor Response Assessment in Metastatic Breast Cancer. Clinical Breast Cancer, 2013, 13, 24-30.	1.1	33
123	High-Density and Very-Low-Density LipoproteinÂHave Opposing Roles in Regulating Tumor-Initiating Cells and Sensitivity to Radiation in Inflammatory Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 91, 1072-1080.	0.4	33
124	MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. Modern Pathology, 2016, 29, 330-346.	2.9	33
125	Circulating Tumor Cells and Biomarkers: Implications for Personalized Targeted Treatments for Metastatic Breast Cancer. Breast Journal, 2010, 16, 327-330.	0.4	32
126	Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12780-12785.	3.3	31

#	Article	IF	Citations
127	Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression. Breast Cancer Research and Treatment, 2017, 164, 57-67.	1.1	31
128	Improved Locoregional Control in a Contemporary Cohort of Nonmetastatic Inflammatory Breast Cancer Patients Undergoing Surgery. Annals of Surgical Oncology, 2017, 24, 2981-2988.	0.7	30
129	CSF-1/CSF-1R axis is associated with epithelial/mesenchymal hybrid phenotype in epithelial-like inflammatory breast cancer. Scientific Reports, 2018, 8, 9427.	1.6	30
130	Gonadal failure after treatment of hematologic malignancies: from recognition to management for health-care providers. Nature Clinical Practice Oncology, 2008, 5, 78-89.	4.3	29
131	Decorin-mediated suppression of tumorigenesis, invasion, and metastasis in inflammatory breast cancer. Communications Biology, 2021, 4, 72.	2.0	29
132	Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clinical Cancer Research, 2021, 27, 5365-5375.	3.2	29
133	Gene Signatureâ€“Guided Dasatinib Therapy in Metastatic Breast Cancer. Clinical Cancer Research, 2014, 20, 5265-5271.	3.2	28
134	Association between weight gain during adjuvant chemotherapy for earlyâ€stage breast cancer and survival outcomes. Cancer Medicine, 2017, 6, 2515-2522.	1.3	28
135	Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory BreastÂCancer. Clinical Breast Cancer, 2018, 18, e73-e77.	1.1	28
136	Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Investigational New Drugs, 2019, 37, 345-351.	1.2	28
137	Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer. Scientific Reports, 2020, 10, 8537.	1.6	28
138	Bcl-2 Antisense Oligonucleotide Overcomes Resistance to E1A Gene Therapy in a Low HER2-Expressing Ovarian Cancer Xenograft Model. Cancer Research, 2005, 65, 8406-8413.	0.4	27
139	Identification of frequent somatic mutations in inflammatory breast cancer. Breast Cancer Research and Treatment, 2017, 163, 263-272.	1.1	27
140	Phase II Study of Gonadotropinâ€Releasing Hormone Analog for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients. Oncologist, 2012, 17, 233-238.	1.9	26
141	Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 242-247.	0.6	26
142	Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux. Oncogene, 2019, 38, 2135-2150.	2.6	26
143	Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer. Breast Cancer Research and Treatment, 2013, 137, 523-531.	1.1	25
144	Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. Journal of the National Cancer Institute, 2015, 107, djv250.	3.0	25

#	Article	IF	Citations
145	Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC). Neoplasia, 2017, 19, 564-573.	2.3	25
146	Impact of Statin Use on Outcomes in Triple Negative Breast Cancer. Journal of Cancer, 2017, 8, 2026-2032.	1.2	25
147	Targeting Signaling Pathways in Inflammatory Breast Cancer. Cancers, 2020, 12, 2479.	1.7	25
148	NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis. Journal of the National Cancer Institute, 2022, 114, 579-591.	3.0	25
149	Non-glycanated Decorin Is a Drug Target on Human Adipose Stromal Cells. Molecular Therapy - Oncolytics, 2017, 6, 1-9.	2.0	24
150	Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. American Journal of Hematology, 2001, 67, 227-233.	2.0	23
151	The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. Biology of Blood and Marrow Transplantation, 2004, 10, 794-804.	2.0	23
152	Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy. Molecular Cancer Therapeutics, 2007, 6, 227-235.	1.9	23
153	MEK1/2 Inhibitor Selumetinib (AZD6244) Inhibits Growth of Ovarian Clear Cell Carcinoma in a PEA-15â€“Dependent Manner in a Mouse Xenograft Model. Molecular Cancer Therapeutics, 2012, 11, 360-369.	1.9	23
154	EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer. Journal of Experimental and Clinical Cancer Research, 2014, 33, 58.	3.5	23
155	NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in nonâ€inflammatory breast cancers. Molecular Oncology, 2020, 14, 504-519.	2.1	23
156	EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStreamÂ® in patients with breast cancer treated with primary systemic therapy. PLoS ONE, 2020, 15, e0229903.	1.1	23
157	Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt. Journal of Cancer, 2011, 2, 435-442.	1.2	22
158	Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center. Leukemia and Lymphoma, 2012, 53, 1239-1241.	0.6	22
159	Latest biopsy approach for suspected metastases in patients with breast cancer. Nature Reviews Clinical Oncology, 2013, 10, 711-719.	12.5	22
160	Aurora kinase-A overexpression in mouse mammary epithelium induces mammary adenocarcinomas harboring genetic alterations shared with human breast cancer. Carcinogenesis, 2016, 37, bgw097.	1.3	22
161	Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. American Journal of Clinical Pathology, 2018, 149, 253-261.	0.4	22
162	Patient reported outcomes can improve performance status assessment: a pilot study. Journal of Patient-Reported Outcomes, 2019, 3, 41.	0.9	22

#	Article	IF	Citations
163	A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. British Journal of Cancer, 2019, 120, 1105-1112.	2.9	22
164	Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. OncoImmunology, 2021, 10, 1929724.	2.1	22
165	Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget, 2016, 7, 76362-76373.	0.8	22
166	Silencing Kinase-Interacting Stathmin Gene Enhances Erlotinib Sensitivity by Inhibiting Ser10 p27 Phosphorylation in Epidermal Growth Factor Receptorâ€“Expressing Breast Cancer. Molecular Cancer Therapeutics, 2010, 9, 3090-3099.	1.9	21
167	Challenging a Traditional Paradigm. Plastic and Reconstructive Surgery, 2015, 135, 262e-269e.	0.7	21
168	MiR-33a Decreases High-Density Lipoprotein-Induced Radiation Sensitivity inÂBreast Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 95, 791-799.	0.4	21
169	E1A: Tumor suppressor or oncogene? Preclinical and clinical investigations ofE1A gene therapy. Breast Cancer, 2001, 8, 285-293.	1.3	20
170	Cyclin Aâ€“associated kinase activity is needed for paclitaxel sensitivity. Molecular Cancer Therapeutics, 2005, 4, 1039-1046.	1.9	20
171	Expression of phosphoprotein enriched in astrocytes 15ÂkDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis. Journal of Neuro-Oncology, 2010, 100, 449-457.	1.4	20
172	Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation. SpringerPlus, 2014, 3, 166.	1.2	20
173	Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. Journal of Cancer, 2015, 6, 310-318.	1.2	20
174	Androgen receptor expression on circulating tumor cells in metastatic breast cancer. PLoS ONE, 2017, 12, e0185231.	1.1	20
175	Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. Human Pathology, 2018, 77, 121-129.	1.1	20
176	NDRG1 Expression Is an Independent Prognostic Factor in Inflammatory Breast Cancer. Cancers, 2020, 12, 3711.	1.7	20
177	Update on systemic treatment for newly diagnosed inflammatory breast cancer. Journal of Advanced Research, 2021, 29, 1-12.	4.4	20
178	Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: Cytoplasmic sequestration of CDK2 by p27. Gynecologic Oncology, 2011, 122, 641-647.	0.6	19
179	Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with boneâ€only metastases. Cancer, 2012, 118, 2039-2047.	2.0	19
180	High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. Oncologist, 2016, 21, 21-27.	1.9	19

#	Article	IF	Citations
181	Neoadjuvant nab-paclitaxel in the treatment of breast cancer. Breast Cancer Research and Treatment, 2016, 156, 427-440.	1.1	19
182	Outcomes in patients with earlyâ€stage breast cancer who underwent a 21â€gene expression assay. Cancer, 2017, 123, 2422-2431.	2.0	19
183	Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis. Journal of Cancer, 2018, 9, 3640-3646.	1.2	19
184	Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium. Journal of Cancer, 2019, 10, 3344-3351.	1.2	19
185	Phase II study of Radiumâ€223 dichloride combined with hormonal therapy for hormone receptorâ€positive, boneâ€dominant metastatic breast cancer. Cancer Medicine, 2020, 9, 1025-1032.	1.3	19
186	Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion. Molecular Oncology, 2021, 15, 2752-2765.	2.1	19
187	A Brief Review of the Biophysical Hallmarks of Metastatic Cancer Cells. Cancer Hallmarks, 2013, 1, 59-66.	0.9	19
188	18F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1809-1816.	3.3	18
189	Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. Journal of Cancer, 2015, 6, 1306-1319.	1.2	18
190	Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. British Journal of Cancer, 2017, 116, 509-514.	2.9	18
191	Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research. PLoS ONE, 2020, 15, e0231953.	1.1	18
192	A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer. Cancers, 2021, 13, 4839.	1.7	18
193	Inflammatory breast cancer cells are characterized by abrogated TGFÎ²1-dependent cell motility and SMAD3 activity. Breast Cancer Research and Treatment, 2020, 180, 385-395.	1.1	18
194	ABC conceptual model of effective multidisciplinary cancer care. Nature Reviews Clinical Oncology, 2010, 7, 544-547.	12.5	17
195	Aldehyde Dehydrogenase 1 Expression in Inflammatory Breast Cancer as Measured by Immunohistochemical Staining. Clinical Breast Cancer, 2014, 14, e81-e88.	1.1	17
196	Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype. PLoS ONE, 2019, 14, e0222336.	1.1	17
197	Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Research and Treatment, 2019, 175, 339-351.	1.1	17
198	Initial Staging Impact of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Locally Advanced Breast Cancer. Oncologist, 2011, 16, 772-782.	1.9	16

#	Article	IF	Citations
199	Breast Cancer Biomarkers: Utility in Clinical Practice. Current Breast Cancer Reports, 2013, 5, 284-292.	0.5	16
200	Bisphosphorylated PEA-15 Sensitizes Ovarian Cancer Cells to Paclitaxel by Impairing the Microtubule-Destabilizing Effect of SCLIP. Molecular Cancer Therapeutics, 2013, 12, 1099-1111.	1.9	16
201	Thrombocytosis as a prognostic factor in inflammatory breast cancer. Breast Cancer Research and Treatment, 2017, 166, 819-832.	1.1	16
202	Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center. PLoS ONE, 2018, 13, e0204372.	1.1	16
203	Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer. Breast Cancer Research and Treatment, 2019, 176, 545-556.	1.1	16
204	Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation. Haematologica, 2005, 90, 1725-6.	1.7	16
205	Reverse-Phase Protein Array for Prediction of Patients at Low Risk of Developing Bone Metastasis From Breast Cancer. Oncologist, 2014, 19, 909-914.	1.9	15
206	Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. Molecular Cancer Therapeutics, 2015, 14, 2687-2699.	1.9	15
207	Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference. Journal of Cancer, 2017, 8, 3607-3614.	1.2	15
208	Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes. European Journal of Surgical Oncology, 2020, 46, 1588-1595.	0.5	15
209	Identification of the JNK-Active Triple-Negative Breast Cancer Cluster Associated With an Immunosuppressive Tumor Microenvironment. Journal of the National Cancer Institute, 2022, 114, 97-108.	3.0	15
210	Primary malignant teratoma of the thyroid gland: Report and discussion of two cases. , 1998, 20, 649-653.		14
211	The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer. PLoS ONE, 2016, 11, e0152585.	1.1	14
212	Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. Journal of Cancer, 2017, 8, 2004-2009.	1.2	14
213	BRCA mutations in women with inflammatory breast cancer. Cancer, 2018, 124, 466-474.	2.0	14
214	Imaging features of triple-negative breast cancers according to androgen receptor status. European Journal of Radiology, 2019, 114, 167-174.	1.2	14
215	The CD151â€midkine pathway regulates the immune microenvironment in inflammatory breast cancer. Journal of Pathology, 2020, 251, 63-73.	2.1	14
216	Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathwayâ€“Dependent Apoptosis. Molecular Cancer Therapeutics, 2021, 20, 296-306.	1.9	14

#	Article	IF	Citations
217	Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkinâ€™s Lymphoma (NHL).. Blood, 2006, 108, 315-315.	0.6	14
218	Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes. Oncotarget, 2017, 8, 70481-70495.	0.8	14
219	Clinically relevant inflammatory breast cancer patient-derived xenograftâ€“derived ex vivo model for evaluation of tumor-specific therapies. PLoS ONE, 2018, 13, e0195932.	1.1	13
220	Ablation of Stromal Cells with a Targeted Proapoptotic Peptide Suppresses Cancer Chemotherapy Resistance and Metastasis. Molecular Therapy - Oncolytics, 2020, 18, 579-586.	2.0	13
221	Information Sharing and Case Conference Among the Multidisciplinary Team Improve Patientsâ€™ Perceptions of Care. Open Nursing Journal, 2011, 5, 79-85.	0.2	13
222	Whatâ€™s Past Is Prologue: Lessons Learned and the Need for Further Development of Allogeneic Hematopoietic Stem Cell Transplantation for Renal Cell Carcinoma. Biology of Blood and Marrow Transplantation, 2007, 13, 31-33.	2.0	12
223	Prognostic Impact of Phosphorylated HER-2 in HER-2+ Primary Breast Cancer. Oncologist, 2011, 16, 956-965.	1.9	12
224	Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy. Breast Cancer Research and Treatment, 2016, 160, 101-109.	1.1	12
225	Factors associated with improved outcomes for metastatic inflammatory breast cancer patients. Breast Cancer Research and Treatment, 2018, 169, 615-623.	1.1	12
226	Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery?. Annals of Surgical Oncology, 2020, 27, 4603-4612.	0.7	12
227	Targeted therapy in inflammatory breast cancer. Cancer, 2010, 116, 2758-2759.	2.0	11
228	A Comparison of Epidemiology, Biology, and Prognosis of Inflammatory Breast Cancer in Japanese and US Populations. Clinical Breast Cancer, 2013, 13, 460-464.	1.1	11
229	Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer. Cancer, 2017, 123, 2618-2625.	2.0	11
230	Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer, 2018, 124, 2299-2305.	2.0	11
231	Use of Wearable Activity Tracker in Patients With Cancer Undergoing Chemotherapy: Toward Evaluating Risk of Unplanned Health Care Encounters. JCO Clinical Cancer Informatics, 2020, 4, 839-853.	1.0	11
232	The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer. Annals of Surgical Oncology, 2021, 28, 4265-4274.	0.7	11
233	Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer. Cancers, 2021, 13, 2650.	1.7	11
234	A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer. Scientific Reports, 2021, 11, 22242.	1.6	11

#	Article	IF	Citations
235	Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series. International Journal of Clinical Oncology, 2011, 16, 596-600.	1.0	10
236	Effect of 21-Gene RT-PCR Assay on Adjuvant Therapy and Outcomes in Patients With Stage I Breast Cancer. Clinical Breast Cancer, 2015, 15, 458-466.	1.1	10
237	Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer. Cancer Letters, 2015, 356, 374-381.	3.2	10
238	Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clinical Breast Cancer, 2018, 18, e1283-e1288.	1.1	10
239	Optimal Supportive Care for Patients With Metastatic Breast Cancer According to Their Disease Progression Phase. JCO Oncology Practice, 2021, 17, 177-183.	1.4	10
240	PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening. Biomedicines, 2021, 9, 740.	1.4	10
241	Inflammatory breast cancer appearance at presentation is associated with overall survival. Cancer Medicine, 2021, 10, 6261-6272.	1.3	10
242	Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes. Breast Cancer Research and Treatment, 2018, 171, 501-511.	1.1	10
243	Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clinical Cancer Research, 2022, 28, 2878-2889.	3.2	10
244	Pilot Study of Targeted Skeletal Radiation Therapy for Bone-Only Metastatic Breast Cancer. Clinical Breast Cancer, 2009, 9, 173-177.	1.1	9
245	Targeted Therapies in Triple-Negative Breast Cancer: Failure and Future. Women's Health, 2015, 11, 1-5.	0.7	9
246	Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel. Journal of Cancer, 2016, 7, 947-956.	1.2	9
247	Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status. Journal of Cancer, 2017, 8, 1045-1052.	1.2	9
248	Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer. Molecular Cancer Therapeutics, 2019, 18, 399-412.	1.9	9
249	MEK and PI3K catalytic activity as predictor of the response to molecularly targeted agents in triple-negative breast cancer. Biochemical and Biophysical Research Communications, 2017, 489, 484-489.	1.0	9
250	Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy. JCO Precision Oncology, 2022, 6, e2000368.	1.5	9
251	Expression of androgen receptor in inflammatory breast cancer and its clinical relevance. Cancer, 2014, 120, 1775-1779.	2.0	8
252	Excellent Locoregional Control in Inflammatory Breast Cancer With a Personalized Radiation Therapy Approach. Practical Radiation Oncology, 2019, 9, 402-409.	1.1	8

#	Article	IF	Citations
253	Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers. Genome Medicine, 2021, 13, 70.	3.6	8
254	Ensemble of nucleic acid absolute quantitation modules for copy number variation detection and RNA profiling. Nature Communications, 2022, 13, 1791.	5.8	8
255	High-Dose Chemotherapy with Hematopoietic Stem-Cell Transplantation for Breast Cancer: Current Status, Future Trends. Clinical Breast Cancer, 2000, 1, 197-209.	1.1	7
256	Predicting outcome based on swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection. Biology of Blood and Marrow Transplantation, 2003, 9, 330-340.	2.0	7
257	Serum HER2 levels determined by two methods in patients with metastatic breast cancer. International Journal of Clinical Oncology, 2012, 17, 55-62.	1.0	7
258	Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope. Bioorganic and Medicinal Chemistry, 2021, 32, 116013.	1.4	7
259	Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. Annals of Surgical Oncology, 2021, 28, 8610-8621.	0.7	7
260	Estrogen Receptor Î²-Mediated Inhibition of Actin-Based Cell Migration Suppresses Metastasis of Inflammatory Breast Cancer. Cancer Research, 2021, 81, 2399-2414.	0.4	7
261	Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer. Oncotarget, 2018, 9, 6872-6882.	0.8	7
262	Harnessing graftâ€versusâ€malignancy: nonâ€myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. British Journal of Haematology, 2000, 111, 18-29.	1.2	6
263	Metastasis in the Breast Mimicking Inflammatory Breast Cancer. Journal of Clinical Oncology, 2012, 30, e202-e206.	0.8	6
264	Clinical Characteristics and Outcome of Bone-Only Metastasis in Inflammatory and Noninflammatory Breast Cancers. Clinical Breast Cancer, 2015, 15, 37-42.	1.1	6
265	Prediction of Bone Metastasis in Inflammatory Breast Cancer Using a Markov Chain Model. Oncologist, 2019, 24, 1322-1330.	1.9	6
266	A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores. Breast Cancer Research and Treatment, 2021, 189, 455-461.	1.1	6
267	ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells. Biomedicines, 2021, 9, 1410.	1.4	6
268	Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC. Npj Breast Cancer, 2022, 8, 12.	2.3	6
269	Fatal Salmonella group G enteritis mimicking intestinal graft-versus-host disease in a bone marrow transplant recipient. Transplant Infectious Disease, 2001, 3, 29-33.	0.7	5
270	Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells. Breast Cancer Research, 2007, 9, R41.	2.2	5

#	Article	IF	Citations
271	Interleukin-2 and granulocyteâ€“macrophageâ€“colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. International Journal of Hematology, 2009, 90, 627-634.	0.7	5
272	Novel Functional Assay for Spindle-Assembly Checkpoint by Cyclin-Dependent Kinase Activity to Predict Taxane Chemosensitivity in Breast Tumor Patient. Journal of Cancer, 2013, 4, 697-702.	1.2	5
273	Location of Receipt of Initial Treatment and Outcomes in Long-Term Breast Cancer Survivors. PLoS ONE, 2017, 12, e0170081.	1.1	5
274	Lack of Breastfeeding History in Parous Women with Inflammatory Breast Cancer Predicts Poor Disease-Free Survival. Journal of Cancer, 2017, 8, 1726-1732.	1.2	5
275	Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation. Journal of Cancer, 2017, 8, 1009-1017.	1.2	5
276	Low-dimensional dynamical characterization of human performance of cancer patients using motion data. Clinical Biomechanics, 2018, 56, 61-69.	0.5	5
277	Survivorship and Advocacy in Inflammatory Breast Cancer. Journal of Cancer, 2018, 9, 1430-1436.	1.2	5
278	Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591878685.	1.4	5
279	Non-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin. Cells, 2020, 9, 515.	1.8	5
280	Inflammatory Breast Cancer at the Extremes of Age. Annals of Surgical Oncology, 2021, 28, 5626-5634.	0.7	5
281	ZevalinÂ®/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status.. Blood, 2007, 110, 620-620.	0.6	5
282	High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy. Bone Marrow Transplantation, 2006, 37, 929-935.	1.3	4
283	Natural History of Metastatic Renal Cell Carcinoma in Patients Who Underwent Consultation for Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 975-985.	2.0	4
284	Is High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Breast Cancer Patients a Done Deal?. Women's Health, 2010, 6, 481-485.	0.7	4
285	Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation. Journal of Cancer, 2013, 4, 679-685.	1.2	4
286	In response to â€œoutcomes of patients with inflammatory breast cancer treated by breast conserving surgeryâ€: the argument against breast conservation and sentinel lymph node biopsy in IBC. Breast Cancer Research and Treatment, 2017, 165, 779-781.	1.1	4
287	Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic. JCO Clinical Cancer Informatics, 2020, 4, 583-601.	1.0	4
288	Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. BMC Cancer, 2020, 20, 430.	1.1	4

#	Article	IF	Citations
289	The Prognostic Impact of Body Composition for Locally Advanced Breast Cancer Patients Who Received Neoadjuvant Chemotherapy. Cancers, 2021, 13, 608.	1.7	4
290	Abstract P3-01-10: Ndrg1-egfr axis in inflammatory breast cancer tumorigenesis and brain metastasis. , 2020, , .		4
291	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients Aged 65 Years or Older with AML and MDS.. Blood, 2004, 104, 2301-2301.	0.6	4
292	Open-label phase Ib study of entinostat (E), and lapatinib (L) alone, and in combination with trastuzumab (T) in patients (pts) with HER2+ metastatic (mHER2+) breast cancer after progression on trastuzumab.. Journal of Clinical Oncology, 2016, 34, 609-609.	0.8	4
293	Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers, 2022, 14, 1323.	1.7	4
294	Graftâ€"Versusâ€"Breast Cancer Effect by Allogeneic Hematopoietic Stem-Cell Transplantation: A Possible New Frontier. Journal of Clinical Oncology, 2004, 22, 3846-3847.	0.8	3
295	Impact of clinical trial on survival outcomes. Breast Cancer Research and Treatment, 2016, 159, 273-281.	1.1	3
296	Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer. European Journal of Cancer, 2018, 89, 64-71.	1.3	3
297	The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer. Journal of Cancer, 2019, 10, 2635-2642.	1.2	3
298	Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review. PLoS ONE, 2021, 16, e0250057.	1.1	3
299	Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER2-negative inflammatory breast cancer.. Journal of Clinical Oncology, 2016, 34, 1087-1087.	0.8	3
300	Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape. Expert Opinion on Therapeutic Targets, 2022, 26, 405-425.	1.5	3
301	Bone Metastases. , 2012, , 591-609.		2
302	Reply to â€˜A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: A large population-based study in the Surveillance, Epidemiology, and End Results database 18â€™. Breast, 2018, 39, 148-149.	0.9	2
303	The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2â^') metastatic breast cancer. Breast Cancer Research and Treatment, 2020, 183, 729-739.	1.1	2
304	Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab. Oncologist, 2020, 25, e909-e919.	1.9	2
305	Primary malignant teratoma of the thyroid gland: Report and discussion of two cases. , 1998, 20, 649.		2
306	Stem Cell Transplantation with 90yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies.. Blood, 2009, 114, 868-868.	0.6	2

#	Article	IF	Citations
307	Correlation of circulating tumor cells (CTCs) with peripheral blood leukocytes to predict outcome in metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2016, 34, 11532-11532.	0.8	2
308	Immune and molecular determinants of response to neoadjuvant chemotherapy in inflammatory breast cancer.. Journal of Clinical Oncology, 2017, 35, 11501-11501.	0.8	2
309	A gene signature consisting of ubiquitin ligases and deubiquitinating enzymes of SKP2 is associated with clinical outcome in breast cancer. Scientific Reports, 2022, 12, 2478.	1.6	2
310	Advances in Oncology in US and Japan: Focusing on Cancer and Infectious Diseases. World Journal of Oncology, 2021, 12, 183-194.	0.6	2
311	Long-term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement. Annals of Surgical Oncology, 0, , .	0.7	2
312	The Emerging Impact of Social Media on Cancer Patient Education in Japan. Oncologist, 2018, 23, e105-e106.	1.9	1
313	Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer. Cancers, 2020, 12, 3105.	1.7	1
314	Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression. Breast Cancer Research and Treatment, 2021, 189, 333-345.	1.1	1
315	Immunotherapy with Donor Leukocyte Infusions (DLIS) in Relapsed Hodgkinâ€™s Disease (HD) Following Allogeneic Stem Cell Transplantation (ALLO-SCT): CD3+ Cell Dose, GVHD and Disease Response.. Blood, 2004, 104, 1654-1654.	0.6	1
316	Targeted Radiotherapy to the Skeleton Using 166Ho-DOTMP with Autologous Stem Cell Transplantation for Patients with Bone-Only Metastatic Breast Cancer.. Blood, 2004, 104, 5239-5239.	0.6	1
317	Breast cancer evaluation and targeted investigational therapy (BEAT-IT): A pilot prospective tissue testing to guide clinical trial selection.. Journal of Clinical Oncology, 2013, 31, 532-532.	0.8	1
318	Outcomes after chemotherapy in early-stage breast cancer (EBC) patients who underwent a 21-gene expression assay.. Journal of Clinical Oncology, 2016, 34, 559-559.	0.8	1
319	Leukemia-Associated Primary Granule Proteins (PGPs) Elastase-2 and Proteinase-3 Are Aberrantly Expressed in Solid Tumors: A Potential Therapeutic Target for PR1-Directed Immunotherapy. Blood, 2008, 112, 5440-5440.	0.6	1
320	Stem Cell Transplantation for Metastatic and High-Risk Nonmetastatic Breast Cancer: A Novel Treatment Approach. , 2008, , 387-410.		0
321	Lapatinib in the Treatment of Breast Cancer. Clinical Medicine Therapeutics, 2009, 1, CMT.S52.	0.1	0
322	Signaling Pathways in Inflammatory Breast Cancer. , 2012, , 151-160.		0
323	Reply to â€˜Comment on â€˜Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapyâ€™â€™. British Journal of Cancer, 2017, 116, e11-e11.	2.9	0
324	Reply to Diagnosis of patients with inflammatory breast cancer is a problematic issue. Cancer, 2018, 124, 866-866.	2.0	0

#	Article	IF	Citations
325	Bone Metastases: Mechanisms of the Metastatic Process, Imaging and Therapy. Seminars in Ultrasound, CT and MRI, 2021, 42, 164-183.	0.7	0
326	Hepatitis C (HC) Virus Infection Is Associated with Worse Survival after Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) for Hematological Malignancies.. Blood, 2007, 110, 48-48.	0.6	0
327	Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL).. Blood, 2009, 114, 3213-3213.	0.6	0
328	Systemic and Targeted Therapy. , 2012, , 85-99.		0
329	Angiogenesis and Lymphangiogenesis in IBC: Insights from a Genome-Wide Gene Expression Profiling Study. , 2012, , 225-242.		0
330	High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Inflammatory Breast Cancer. , 2012, , 127-138.		0
331	Bone Metastasis of Breast Cancer. , 2013, , 189-209.		0
332	Inflammatory and Locally Advanced Breast Cancer. , 2016, , 411-435.		0
333	A target of potential RELAvance in inflammatory breast cancer. Oncotarget, 2017, 8, 25835-25836.	0.8	0
334	Trials and Tribulations in Developing Clinical Trials of Gene Therapy. , 2007, , 387-398.		0
335	â€œWhy and Whatâ€•for the optimal management of inflammatory breast cancer. Chinese Clinical Oncology, 2021, 10, 54-54.	0.4	0
336	Title is missing!. , 2020, 15, e0231953.		0
337	Title is missing!. , 2020, 15, e0231953.		0
338	Title is missing!. , 2020, 15, e0231953.		0
339	Title is missing!. , 2020, 15, e0231953.		0
340	Title is missing!. , 2020, 15, e0231953.		0
341	Title is missing!. , 2020, 15, e0231953.		0